Tech Company Financing Transactions
Neuron23 Funding Round
Neuron23, based in San Francisco, secured $96.5 million from Acorn Bioventures, Blue Owl Capital and HBM Healthcare Investments.
Transaction Overview
Company Name
Announced On
6/24/2025
Transaction Type
Venture Equity
Amount
$96,500,000
Round
Series D
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
681 Gateway Blvd. 3rd Floor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, USA, and Munich, Germany. Working with leading geneticists and valued partners like Origenis, Neuron23 leverages genetic breakthroughs and artificial intelligence technology to discover promising approaches and develop new drugs more efficiently than ever before.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nancy Stagliano
Vice President
Zhonghua Pei
Vice President
Steve Wood
VP - Bus. Development
Adam Knight
VP - R & D
Luc Desnoyers
VP - R & D
Arash Rassoulpour
Browse more venture capital transactions:
Prev: 6/24/2025: SWARM Biotactics venture capital transaction
Next: 6/24/2025: Claira venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. VC transactions on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs